Biogen and Dayra Therapeutics have announced a strategic collaboration focused on developing macrocyclic peptides for next-generation peptide therapeutics. This partnership aims to leverage Dayra’s expertise in macrocyclic chemistry to address complex immunological conditions that remain challenging for conventional treatments.
The collaboration combines Biogen’s extensive experience in neurological and immunological drug development with Dayra’s innovative platform for designing highly selective and stable macrocyclic peptides. These molecules have the potential to offer more effective therapies with fewer side effects, opening new avenues in the treatment of autoimmune and inflammatory diseases.
“We are excited to join forces with Biogen to push the boundaries of peptide therapeutics,” said Dayra spokesperson. “Our macrocyclic peptide platform is uniquely suited to create potent and selective molecules that could transform the management of immunological conditions.”
This partnership represents a significant step forward in the growing field of macrocyclic peptide drug discovery, highlighting the increasing importance of collaboration between biotech innovators and established pharmaceutical leaders.
